News

Baudax Bio (BXRX) – Adjusting price target for stock split and updated funding expectations

Health
0 min read

Wednesday, February 16, 2022

Baudax Bio (BXRX)
Adjusting price target for stock split and updated funding expectations

Baudax Bio is a biopharmaceutical company focused on developing therapies for post-operative pain, peri-operative pain, and anesthesia. The company currently has one approved therapy in ANJESO for post-operative pain. Proprietary ANJESO (meloxicam) injection is the first and only once-daily IV analgesic. The company also has a pipeline of early-stage candidates with two novel neuromuscular blocking agents (NMBAs), a proprietary related reversal agent to their NMBAs, and Dex-IN, an intranasal formulation of dexmedetomidine (Dex) that has sedative, analgesic, and anti-anxiety properties.

Gregory Aurand, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Board approved a 1:35 reverse split. A shareholder meeting held February 9th approved an amendment granting the Board of Directors authority to effect a reverse split. Last night the Board approved and filed a 1 for 35 reverse split, effective February 16, 2022. This split will help BXRX regain Nasdaq compliance.

    New CDC proposal encourages non-opioid therapies.  Last updated in 2016, the CDC has opened a public comment 60-day period for updated guidelines. The updated guidelines remove hard limitations on opioid dosage but, given opioid side effects and addiction problems, continue to recommend non-opioid therapies, like ANJESO, whenever possible to treat chronic and acute pain …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Share

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.